Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study | |
Bachy, Emmanuel27,28; Savage, Kerry J.26; Huang, Huiqiang25; Kwong, Yok-Lam24; Gritti, Giuseppe23; Zhang, Qingyuan22; Liberati, Anna Marina21; Cao, Junning20; Yang, Haiyan19; Hao, Siguo18 | |
刊名 | BLOOD ADVANCES |
2023-08-22 | |
卷号 | 7 |
ISSN号 | 2473-9529 |
DOI | 10.1182/bloodadvances.2022009575 |
通讯作者 | Zinzani, Pier Luigi(pierluigi.zinzani@unibo.it) |
英文摘要 | Patients with relapsed/refractory (R/R) mature T-and natural killer (NK)-cell neoplasms lack effective treatments after failure of standard therapies. This phase 2 study evaluated the efficacy and safety of the programmed cell death protein 1 inhibitor tislelizumab in these patients. Seventy-seven patients were treated with 200 mg tislelizumab every 3 weeks. Twenty-two patients with extranodal NK-/T-cell lymphomas were enrolled in cohort 1; 44 patients with peripheral T-cell lymphoma (PTCL) were enrolled in cohort 2 (21 patients had PTCL not otherwise specified, 11 patients had angioimmunoblastic T-cell lymphoma, and 12 patients had anaplastic large-cell lymphoma). Cohort 3 comprised 11 patients with cutaneous T-cell lymphoma, of which 8 patients had mycosis fungoides (MF) and 3 had S e & PRIME;zary syndrome. Of the 77 patients, 76.6% had advanced-stage disease, 51.9% had refractory disease, and 49.4% received & GE;3 prior systemic regimens. Promising efficacy was observed in cohort 3 (median follow-up [FU], 16.6 months; overall response rate [ORR], 45.5%; complete response [CR], 9.1%; median duration of response [DOR], 11.3 months; median progression -free survival, 16.8 months; median overall survival, not reached). Modest efficacy was observed in cohort 1 (median FU, 8.4 months; ORR, 31.8%; CR, 18.2%; median DOR, not reached) and cohort 2 (median FU, 9.3 months; ORR, 20.5%; CR, 9.1%; median DOR, 8.2 months). Most treatment-related adverse events were grade 1 or 2, and the safety profile was consistent with the known safety profile of tislelizumab. In conclusion, tislelizumab was well tolerated, achieving modest efficacy in R/R mature T-and NK-cell neoplasms, with some long-lasting remissions. This trial was registered at www.clinicaltrials.gov as #NCT03493451. |
资助项目 | BeiGene Co., Ltd. ; BeiGene |
WOS关键词 | MYCOSIS-FUNGOIDES ; RESPONSE CRITERIA ; HODGKIN-LYMPHOMA ; SEZARY-SYNDROME ; PD1 BLOCKADE ; III TRIAL ; SURVIVAL ; PROGRESSION ; NIVOLUMAB ; PD-1 |
WOS研究方向 | Hematology |
语种 | 英语 |
出版者 | ELSEVIER |
WOS记录号 | WOS:001063440100001 |
资助机构 | BeiGene Co., Ltd. ; BeiGene |
内容类型 | 期刊论文 |
源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/132594] |
专题 | 中国科学院合肥物质科学研究院 |
通讯作者 | Zinzani, Pier Luigi |
作者单位 | 1.Univ Bologna, Dipartimento Medicina Specialist Diagnost Speri, Bologna, Italy 2.IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy 3.BeiGene USA Inc, San Mateo, CA USA 4.BeiGene Shanghai Co Ltd, Shanghai, Peoples R China 5.Osped Policlin San Martino, Genoa, Italy 6.Peking Univ Third Hosp, Beijing, Peoples R China 7.Peking Union Med Coll Hosp, Beijing, Peoples R China 8.Beijing Hosp, Beijing, Peoples R China 9.Inst dHematol Basse Normandie, Caen, France 10.IRCCS San Raffaele Sci Inst, Lymphoma Unit, Milan, Italy |
推荐引用方式 GB/T 7714 | Bachy, Emmanuel,Savage, Kerry J.,Huang, Huiqiang,et al. Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study[J]. BLOOD ADVANCES,2023,7. |
APA | Bachy, Emmanuel.,Savage, Kerry J..,Huang, Huiqiang.,Kwong, Yok-Lam.,Gritti, Giuseppe.,...&Zinzani, Pier Luigi.(2023).Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study.BLOOD ADVANCES,7. |
MLA | Bachy, Emmanuel,et al."Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study".BLOOD ADVANCES 7(2023). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论